Suppressed expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 6, 2010, Pages 608-617

  Zakharov, Vladislav ^a   Lin, Hsueh Kung ^a,b   Azzarello, Joseph ^a   McMeekin, Scott ^a   Moore, Kathleen N ^a   Penning, Trevor M ^c   Fung, Kar Ming ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aldo keto reductase; Endomtrial cancer; Estrogen; Progesterone; Prostaglandin

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; BIOSYNTHESIS; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM TUMOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM;

3-HYDROXYSTEROID DEHYDROGENASES; ADENOCARCINOMA; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IMMUNOHISTOCHEMISTRY; TUMOR MARKERS, BIOLOGICAL;

EID: 77956028572     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ito K, Utsunomiya H, Yaegashi N and Sasano H. Biological roles of estrogen and progesterone in human endometrial carcinoma-new developments in potential endocrine therapy for endometrial cancer. Endocr J 2007; 54: 667-679.
2. Berstein LM, Tchernobrovkina AE, Gamajunova VB, Kovalevskij AJ, Vasilyev DA, Chepik OF, Turkevitch EA, Tsyrlina EV, Maximov SJ, Ashrafian LA and Thijssen JH. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol 2003; 129: 245-249.
3. Legro RS, Kunselman AR, Miller SA and Satyaswaroop PG. Role of androgens in the growth of endometrial carcinoma: an in vivo animal model. Am J Obstet Gynecol 2001; 184: 303-308.
4. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B and van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274-277.
5. Labied S, Kajihara T, Madureira PA, Fusi L, Jones MC, Higham JM, Varshochi R, Francis JM, Zoumpoulidou G, Essafi A, Fernandez de Mattos S, Lam EW and Brosens JJ. Progestins regulate the expression and activity of the forkhead transcription factor FOXO1 in differentiating human endometrium. Mol Endocrinol 2006; 20: 35-44.
6. Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, Ohuchi N and Sasano H. Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 2005; 12: 701-720.
7. Jez JM, Flynn TG and Penning TM. A new nomenclature for the aldo-keto reductase superfamily. Biochem Pharmacol 1997; 54: 639-647.
8. Jez JM, Bennett MJ, Schlegel BP, Lewis M and Penning TM. Comparative anatomy of the aldoketo reductase superfamily. Biochem J 1997; 326: 625-636.
9. Hyndman D, Bauman DR, Heredia VV and Penning TM. The aldo-keto reductase superfamily homepage. Chem Biol Interact 2003; 143-144: 621-631.
10. Hara A, Matsuura K, Tamada Y, Sato K, Miyabe Y, Deyashiki Y and Ishida N. Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells. Biochem J 1996; 313: 373-376.
11. Dufort I, Soucy P, Labrie F and Luu-The V. Molecular cloning of human type 3 3ahydroxysteroid dehydrogenase that differs from 20a-hydroxysteroid dehydrogenase by seven amino acids. Biochem Biophy Res Communication 1996; 228: 474-479.
12. Deyashiki Y, Ogasawara A, Nakayama T, Nakanishi M, Miyabe Y, Sato K and Hara A. Molecular cloning of two human liver 3a-hydroxysteroid/dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bileacid binder. Biochem J 1994; 299: 545-552.
13. Khanna M, Qin KN, Wang RW and Cheng KC. Substrate specificity, gene structure, and tissuespecific distribution of multiple human 3ahydroxysteroid dehydrogenases. J Biol Chem 1995; 270: 20162-20168.
14. Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA and Penning TM. Expression and characterization of recombinant type 2 3ahydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3a/17b-HSD activity and cellular distribution. Mol Endocrinol 1997; 11: 1971-1984.
15. Dufort I, Rheault P, Huang XF, Soucy P and Luu-The V. Characteristics of a highly labile human type 5 17b-hydroxysteroid dehydrogenase. Endocrinology [1999;] 140: 568-574.
16. 2 11-ketoreductase activity. J Biochem (Tokyo) 1998; 124: 940-946.
17. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N and Ratnam K. Human 3a-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000; 351: 67-77.
18. Penning TM, Steckelbroeck S, Bauman DR, Miller MW, Jin Y, Peehl DM, Fung KM and Lin HK. Aldo-keto reductase (AKR) 1C3: Role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol 2006; 248: 182-191.
19. Ashley RA, Yu Z, Fung KM, Frimberger D, Kropp BP, Penning TM and Lin HK. Developmental Evaluation of Aldo-keto Reductase 1C3 Expression in the Cryptorchid Testis. Urology 2009.
20. Azzarello J, Fung KM and Lin HK. Tissue distribution of human AKR1C3 and rat homolog in adult genitourinary system. J Histochem Cytochem 2008; 56: 853-861.
21. Rizner TL, Smuc T, Rupreht R, Sinkovec J and Penning TM. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 2006; 248: 126-135.
22. Lewis MJ, Wiebe JP and Heathcote JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 2004; 4: 27.
23. Lan Q, Mumford JL, Shen M, Demarini DM, Bonner MR, He X, Yeager M, Welch R, Chanock S, Tian L, Chapman RS, Zheng T, Keohavong P, Caporaso N and Rothman N. Oxidative damagerelated genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 2004; 25: 2177-2181.
24. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, Moriya T, Ito A, Takahashi S, Yamada S, Arai Y and Sasano H. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 2005; 12: 101-107.
25. Fung KM, Samara ENS, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JT, Culkin DJ, Kropp BP, Penning TM and Lin HK. Increased expression of type 2 3a-hydroxysteroid dehydrogenase/type 5 17b-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006; 13: 169-180.
26. Stanbrough M, Bubley G, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG and Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgenindependent prostate cancer. Cancer Res 2006; 66: 2815-2825.
27. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, Nishiyama T, Takahashi K, Hamakubo T, Kodama T and Naito M. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008; 61: 448-454.
28. Azzarello JT, Lin H-K, Gherezghiher A, Zakharov V, Yu Z, Kropp BP, Culkin DJ, Penning TM and Fung K-M. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor. Int J Clin Expt Pathol 2010; in press.
29. Ito K, Utsunomiya H, Suzuki T, Saitou S, Akahira J, Okamura K, Yaegashi N and Sasano H. 17bhydroxysteroid dehydrogenases in human endometrium and its disorders. Mol Cell Endocrinol 2006; 248: 136-140.
30. Lin HK, Steckelbroeck S, Fung KM, Jones AN and Penning TM. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3a-hydroxysteroid dehydrogenase/type 5 17b-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 2004; 69: 795-801.
31. Smuc T and Rizner TL. Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol 2009; 301: 74-82.
32. Nimrod A and Ryan KJ. Aromatization of androgens by human abdominal and breast fat tissue. J Clin Endocrinol Metab 1975; 40: 367-372.
33. Watanabe K, Sasano H, Harada N, Ozaki M, Niikura H, Sato S and Yajima A. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. Am J Pathol 1995; 146: 491-500.
34. Puranen T, Poutanen M, Ghosh D, Vihko P and Vihko R. Characterization of structural and functional properties of human 17 b-hydroxysteroid dehydrogenase type 1 using recombinant enzymes and site-directed mutagenesis. Mol Endocrinol 1997; 11: 77-86.
35. Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO and Andersson S. Expression cloning and characterization of human 17b-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20a-hydroxysteroid dehydrogenase activity. J Biol Chem 1993; 268: 12964-12969.
36. Husen B, Psonka N, Jacob-Meisel M, Keil C and Rune GM. Differential expression of 17b-hydroxysteroid dehydrogenases types 2 and 4 in human endometrial epithelial cell lines. J Mol Endocrinol 2000; 24: 135-144.
37. Utsunomiya H, Suzuki T, Kaneko C, Takeyama J, Nakamura J, Kimura K, Yoshihama M, Harada N, Ito K, Konno R, Sato S, Okamura K and Sasano H. The analyses of 17b-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma. J Clin Endocrinol Metab 2001; 86: 3436-3443.
38. Yang S, Fang Z, Gurates B, Tamura M, Miller J, Ferrer K and Bulun SE. Stromal PRs mediate induction of 17b-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2. Mol Endocrinol 2001; 15: 2093-2105.
39. Carneiro MM, Morsch DM, Camargos AF, Reis FM and Spritzer PM. Androgen receptor and 5areductase are expressed in pelvic endometriosis. Bjog 2008; 115: 113-117.
40. Bukulmez O, Hardy DB, Carr BR, Auchus RJ, Toloubeydokhti T, Word RA and Mendelson CR. Androstenedione up-regulation of endometrial aromatase expression via local conversion to estrogen: potential relevance to the pathogenesis of endometriosis. J Clin Endocrinol Metab 2008; 93: 3471-3477.
41. 2 is a ligand for the adipocyte determination factor PPARg. Cell 1995; 83: 803-812.
42. Ota K, Ito K, Suzuki T, Saito S, Tamura M, Hayashi S, Okamura K, Sasano H and Yaegashi N. Peroxisome proliferator-activated receptor g and growth inhibition by its ligands in uterine endometrial carcinoma. Clin Cancer Res 2006; 12: 4200-4208.
43. 2a-FP receptor interaction in human endometrial adenocarcinomas. Cancer Res 2005; 65: 7707-7716.